MODERATE TO SEVERE PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New psoriasis pill shows promise in 12-Week trial
Disease control Recruiting nowThis study tests a new oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. About 140 adults aged 18-70 will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: NA • Sponsor: Usynova Pharmaceuticals Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for kids with severe psoriasis: major trial launches
Disease control Recruiting nowThis study compares two injectable drugs, bimekizumab and ustekinumab, in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab is more effective at clearing skin symptoms. Participants will receive one of the two treatments a…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New study checks drug levels in breast milk of nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab ends up in the breast milk of mothers who are already taking it for conditions like psoriasis or arthritis. About 20 breastfeeding women will provide milk samples over several weeks. The goal is to understand possible exposure …
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated May 13, 2026 16:02 UTC
-
Psoriasis drug study dives into genetic changes
Knowledge-focused Recruiting nowThis study looks at how bimekizumab changes gene activity in people with moderate to severe plaque psoriasis, with or without psoriatic arthritis. About 90 adults will provide skin samples to measure gene expression changes after 48 weeks of treatment. The goal is to understand h…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC